Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | $12.56B | $116.23 | $122.60 | 5.48% | Buy | 5 | 39.18% | 137.99% | 172.24% | 136.79% | |||
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $3.16B | $25.16 | $38.67 | 53.68% | Strong Buy | 3 | 22.15% | 116.82% | 162.86% | 73.53% | |||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $29.40B | $219.72 | $355.81 | 61.94% | Strong Buy | 16 | 20.89% | 29.01% | 186.00% | 45.31% | |||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $5.91B | $75.79 | $91.29 | 20.45% | Strong Buy | 7 | 19.35% | 39.16% | 38.00% | 27.74% | |||
| VCEL | VERICEL CORP | $2.06B | $40.15 | $62.67 | 56.08% | Strong Buy | 3 | 14.77% | 40.75% | 22.72% | 16.72% | |||
| RPRX | ROYALTY PHARMA PLC | $32.87B | $57.16 | $63.50 | 11.09% | Strong Buy | 6 | 15.46% | 49.52% | 42.19% | 20.83% | |||
| KRYS | KRYSTAL BIOTECH INC | $9.54B | $322.28 | $384.43 | 19.28% | Strong Buy | 7 | 29.78% | 18.72% | 63.71% | 57.71% | |||
| HALO | HALOZYME THERAPEUTICS INC | $12.47B | $109.86 | $101.83 | -7.31% | Buy | 6 | 11.52% | 52.04% | 769.40% | 42.85% | |||
| ZVRA | ZEVRA THERAPEUTICS INC | $593.24M | $9.99 | $26.88 | 169.02% | Strong Buy | 8 | 18.48% | 11.46% | 77.72% | 55.88% | |||
| TGTX | TG THERAPEUTICS INC | $8.31B | $54.29 | $64.00 | 17.89% | Buy | 4 | 28.02% | 8.98% | 101.32% | 37.33% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.07B | $57.18 | $92.00 | 60.90% | Strong Buy | 14 | 13.25% | 150.46% | 25.90% | 13.97% | |||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $15.30B | $235.67 | $290.95 | 23.46% | Strong Buy | 19 | 6.45% | 24.34% | 43.06% | 18.66% | |||
| MDXG | MIMEDX GROUP INC | $669.04M | $4.59 | $7.33 | 59.76% | Strong Buy | 3 | 3.80% | 92.15% | 13.77% | 10.58% | |||
| EXEL | EXELIXIS INC | $14.47B | $58.39 | $52.00 | -10.94% | Hold | 11 | 10.80% | 15.22% | 66.89% | 49.45% | |||
| ADMA | ADMA BIOLOGICS INC | $2.18B | $9.72 | $17.50 | 80.04% | Strong Buy | 2 | 13.23% | 17.15% | 83.21% | 49.64% | |||
| LGND | LIGAND PHARMACEUTICALS INC | $6.04B | $302.96 | $352.63 | 16.39% | Strong Buy | 8 | 16.19% | 13.20% | 29.02% | 12.85% | |||
| VRTX | VERTEX PHARMACEUTICALS INC | $127.93B | $504.73 | $554.64 | 9.89% | Strong Buy | 11 | 9.82% | 13.32% | 36.48% | 26.94% | |||
| UTHR | UNITED THERAPEUTICS CORP | $23.23B | $541.70 | $611.86 | 12.95% | Buy | 7 | 8.30% | 5.45% | 30.47% | 27.01% | |||
| TECH | BIO-TECHNE CORP | $11.35B | $72.40 | $68.33 | -5.62% | Hold | 11 | 8.37% | 31.47% | 19.90% | 16.22% | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.31B | $39.64 | $47.67 | 20.25% | Buy | 6 | 11.63% | 16.79% | 23.24% | 16.92% | |||
| REGN | REGENERON PHARMACEUTICALS INC | $75.69B | $735.20 | $811.14 | 10.33% | Strong Buy | 21 | 9.52% | 18.89% | 24.05% | 18.28% | |||
| VCYT | VERACYTE INC | $3.68B | $45.81 | $56.50 | 23.34% | Strong Buy | 10 | 9.84% | 11.91% | 11.84% | 11.06% | |||
| SPRO | SPERO THERAPEUTICS INC | $69.30M | $1.19 | $6.00 | 404.20% | Buy | 1 | -14.78% | 17.91% | N/A | N/A | |||
| INCY | INCYTE CORP | $23.37B | $115.30 | $124.31 | 7.82% | Buy | 16 | 4.56% | 8.90% | 12.85% | 10.36% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.